

We are delighted to announce that the Ovarian Cancer Midwest Focus (OCMF) conference 2021 will be both an in-person and a virtual conference that will include live streamed discussion rounds with national and international speakers.

Program Chairs:

Martina Bazzaro, Ph.D. - University of Minnesota - Twin Cities Campus
Ilana Chefetz, Ph.D. - The Hormel Institute, University of Minnesota
Ronny Drapkin, M.D., Ph.D. - University of Pennsylvania - Perelman School of Medicine
Melissa Geller, M.D., M.S. - University of Minnesota - Twin Cities Campus
Gottfried E. Konecny, M.D. - University of California - Los Angeles

Wednesday, November 10, 2021

ALL TIMES ARE CENTRAL STANDARD TIME (CST)

Social/Cash bar – 6:00 pm Dinner – 7:00 pm

Location: The Historic Hormel Home, 208 4th Avenue NW, Austin, MN

Thursday, November 11, 2021

Location: The Hormel Institute, Ray Live Learning center, 801 16th Ave NE, Austin, MN 55912

Breakfast - 7:15-8:00

Opening Remarks – 8:00 – 8:05 AM Melissa Geller, MD, MS

Welcome Videos - 8:05-8:10

President Joan Gabel – University of Minnesota Amy Klobuchar - U.S. Senator from Minnesota Michelle Fischbach - U.S. Representative from Minnesota's 7th District

Moderator: Ronny Drapkin, MD, Ph.D.

The Impact of Ovarian Cancer Origins on Early Detection and Prevention Strategies

Tubal Origins and Prevention Strategies:

	08:10 - 08:35 AM	The Origins of Ovarian Precancer Species le-Ming Shih, M.D., Ph.D. – John Hopkins Medicine
	08:35 – 09:00 AM	Opportunistic Salpingectomy: Is it more than just a good idea? David Huntsman, M.D. – University of British Columbia
	09:05 - 09:30 AM	Salpingectomy for ovarian cancer risk reduction in high risk women Karen Lu, M.D. – University of Texas MD Anderson Cancer Center
New Approaches to Early Detection:		
	09:35 - 10:00 AM	Early detection of cancer using cell-free DNA fragmentomes Victor Velculescu, M.D., Ph.D. – Johns Hopkins Medicine
	10:00 – 10:15 AM	Break
	10:15 - 10:40 AM	Utero-tubal lavage for diagnosis of ovarian cancer Keren Levanon, M.D., Ph.D. – Tel Aviv University Chaim Sheba Medical Center
	10:40 – 11:05 AM	Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with Nanoengineered Microfluidic Platforms Andrew Godwin, Ph.D. – University of Kansas Medical Center
	11:05 - 11:30 AM	Question and Answer session
	11:35 - 12:10 PM	Flash Talks from Abstracts
		1) Dual inhibition of ALDH1A and MEK1/2 causes synergistic cell death in high grade serous ovarian cancer triggered by enhanced DNA damage and

high grade serous ovarian cancer triggered by enhanced DNA damage and diminished DNA repair

Imran Khan, Postdoctoral Associate – The Hormel Institute, University of Minnesota

2) USP13 promotes growth and metastasis of high-grade serous ovarian carcinoma in a novel mouse model

Cecil Han, Ph.D. - Georgetown University School of Medicine

3) GLS1 overexpression requires intact ARID1A and is a protective factor in ovarian clear cell carcinoma: differences between experimental models and clinical specimens

Valentino Clemente, Postdoctoral Associate - University of Minnesota

4) Rewiring of the PAX8 regulatory network during the transformation of normal fallopian tube secretory epithelium to high-grade serous ovarian cancer development

Robbin Nameki, Ph.D. Candidate – Samuel Oschin Cancer Center, Cedars-Sinai Medical Center

Question and Answer session

12:10 - 12:40 PM Exhibitor/Sponsor Presentations

- 1) Lori Willcoxon GlaxoSmithKline
- 2) Mike Zinda Repare Therapeutics
- 3) Jeff Hirst Caris
- 4) Dr. Charles Dunton Aspira Question and Answer session

12:40 - 12:50 PM Break – Lunch Begins

Moderator: Ilana Chefetz, Ph.D.

Dynamic Heterogeneity in ovarian cancer

,	•
12:50 - 01:10 PM	Lunch and Learn Histology based Artificial Intelligence strategies for HGSC outcome prediction Thomas Westerling-Bui, Ph.D Aiforia Inc.
01:10 - 01:30 PM	Lunch and Learn – Interested in a specific gene or signature? Online resources will help you plan your next step. Sandra Orsulic, Ph.D UCLA David Geffen School of Medicine
01:30 - 01:40 PM	Break – Lunch Ends
01:40 - 02:05 PM	Exploring the CINful side of high-grade serous ovarian cancer Kirk McManus , Ph.D. – University of Manitoba
02:05 - 02:30 PM	Epigenetic control in tumor immunity and therapy Weiping Zou, M.D., Ph.D. – University of Michigan Medical School
02:30 – 2:55 PM	Malignant and immune cell phenotypic states in high grade serous ovarian cancer Sohrab Shah, Ph.D. – Memorial Sloan Kettering Cancer Center
02:55 - 03:20 PM	Ruvelson Keynote Speaker – Development and characterization of an anti-Claudin-6 (CLDN6) Antibody-Drug Conjugate for the treatment of CLDN6 positive cancer Dennis Slamon, M.D., Ph.D. – University of California at Los Angeles
03:20 - 03:35 PM	Break
03:35 - 04:00 PM	Interconnectivity of cell death pathways Ilana Chefetz, Ph.D. – The Hormel Institute, University of Minnesota

04:00 - 04:25 PM A novel humanized stroma PDX model for therapeutic studies

Ron Buckanovich, M.D., Ph.D. – University of Pittsburgh

04:25 - 04:55 PM Question and Answer session

Closing Remarks - 4:55 - 5:00 pm Ronny Drapkin, MD, Ph.D.

Social/Cash bar/Ping Pong Tournament – 5:00 pm Dinner – 6:00 pm

Location: The Hormel Institute, 801 16th Avenue NE, Austin, MN

Friday, November 12, 2021

Location: The Hormel Institute, Ray Live Learning center, 801 16th Ave NE, Austin, MN 55912

Breakfast - 7:15 - 8:00 AM

Opening Remarks – 8:00 – 8:05 AM, Martina Bazzaro, Ph.D.

Welcome Videos - 8:05 - 8:10

Jakub Tolar, MD, Ph.D. – Dean of Medical School, Vice-President for Clinical Affairs University of Minnesota

Douglas Yee, MD – Director, Masonic Cancer Center, University of Minnesota Tina Smith - U.S. Senator from Minnesota

Moderator: Martina Bazzaro, Ph.D.

Basic mechanisms of chemoresistance in ovarian cancer

08:10 - 08:35 AM	Ruvelson Keynote Speaker Genomic and functional approaches to modeling and targeting cancer aneuploidy Uri Ben-David, Ph.D. – Tel Aviv University
08:35 – 09:00 AM	Targeting Microtubule-Associated Protein Tau in Paclitaxel-sensitive and resistant Models in Ovarian Carcinoma Maria Barbolina, Ph.D. – University of Illinois Cancer Center
09:00 – 09:25 AM	Chromosomal instability sensitizes to paclitaxel Beth Weaver, Ph.D. – University of Wisconsin
09:25 – 09:50 AM	Determinants of p53-dependent tissue-specific gene expression and radio-resistance in vivo James Manfredi, Ph.D. – Icahn School of Medicine at Mount Sinai
09:50 - 10:15 AM	Are ovarian cancers addicted to aneuploidy? Jason Sheltzer, Ph.D. – Cold Spring Harbor Laboratory
10:15 – 10:40 AM	Mechanisms of chromosomal instability indicate therapeutic sensitivities in high grade serous ovarian carcinoma Sarah McClelland, Ph.D. – Barts Cancer Institute

10:40 - 11:10 AM Question and Answer session 11:10 – 11:25 AM Break 11:25 - 12:00 PM Flash Talks from Abstracts 1) Loss of Claudin-4 reduces DNA damage repair and increases sensitivity to PARP inhibitors Benjamin Bitler, Ph.D. - University of Colorado 2) Small extracellular vesicle cargo mediates sensory innervation in ovarian cancer Hunter Reavis, Ph.D. Candidate – University of Pennsylvania Perelman **School of Medicine** 3) High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment Antonio Delgado-Gonzalez, Postdoctoral Research Fellow – Stanford **University School of Medicine** 4) Microenvironment induced epigenetic downregulation of miR-193b via the ERK/EZH2/DNMT1 axis promotes ovarian cancer stemness and metastasis Subramanyam Dasari, Postdoctoral Scholar – Indiana University School of Medicine Question and Answer session 12:00 - 12:30 PM Exhibitor/Sponsor Presentations 1) Brigitte Lawrence – Genentech Oncology 2) Casey Kuenn - Isoplexis Question and Answer session 12:30 - 12:50 PM Break - Lunch Begins Moderator: Gottfried E. Konecny, M.D. Evolving Therapeutic Landscape in OC 12:50 - 01:10 PM Lunch and Learn The DoD OCRP, the Ovarian Cancer Academy and how to apply Karen Wylie, Ph.D. – Department of Defense Ovarian Cancer Research

	Program
01:10 - 01:30 PM	Lunch and Learn What is the problem with our access to clinical trials? Rahel Ghebre, M.D., M.S. – University of Minnesota Medical School
01:30 - 01:40 PM	Break – Lunch Ends
01:40 - 02:05 PM	Treatment of Ovarian Cancer: The World Beyond PARP inhibition Kathleen Moore, M.D. – University of Oklahoma College of Medicine

02:05 - 02:30 PM	Targeting Replication Stress in Ovarian Cancer Panagiotis Konstantinopoulos, M.D., Ph.D. – Harvard Cancer Center
02:30 - 02:55 PM	Novel agent combinations: Targeting adaptive and resistance response Stéphanie Lheureux, M.D., Ph.D. - University of Toronto
02:55 - 03:35 PM	Break
03:35 - 04:00 PM	Moving beyond PARP inhibitors: Progress, Pitfalls and Promises Timothy Yap, Ph.D. – University of Texas MD Anderson Cancer Center
04:00 - 04:25 PM	Targeting <i>CCNE1</i> amplification in ovarian cancernew approaches Fiona Simpkins, M.D. – University of Pennsylvania School of Medicine
04:25 - 04:55 PM	Question and Answer Session

Closing Remarks - 4:55 - 5:00 pm Gottfried E. Konecny, M.D.

Thank You for attending the Ovarian Cancer Midwest Focus Conference

Acknowledgement of Support

We gratefully acknowledge the following organizations for their financial contributions to this conference.

Funders Include:















With Gratitude

On behalf of the OCMF Program Chairs, we would like to express our sincere gratitude to the *Ethel N. Ruvelson Memorial Lectureship in Ovarian Cancer* for their help in supporting this conference. The *Ethel N. Ruvelson Memorial Lectureship in Ovarian Cancer* fund helps us continue to fund vital research lectureships and provide educational programs for our faculty and clinical researchers at the University of Minnesota.